Brought to you by 
NantCell completes second round, gets $30mm from Celgene
16 Jan 2019
Executive Summary
Oncology immunotherapy developer NantCell Inc. (a NantHealth company) raised $30mm through a crossover investment from Celgene. This is the second such round for NantCell and Celgene; NantCell was founded in 2015 with an initial $75mm investment by Celgene, which now holds a 2.8% stake. Announcement of the funding came shortly after Celgene revealed that it would be acquired by BMS for $74bn.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NantCell completes second round, gets $30mm from Celgene
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice